Lesinurad/allopurinol
| Combination of | |
|---|---|
| Lesinurad | urate transporter inhibitor |
| Allopurinol | xanthine oxidase inhibitor |
| Clinical data | |
| Trade names | Duzallo |
| AHFS/Drugs.com | duzallo |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
Lesinurad/allopurinol (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout. It contains 200 mg of lesinurad and 300 mg of allopurinol. In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with allopurinol alone.[1]
References
- ↑ "FDA Clears First Fixed-Dose Combination Treatment for Gout". Medscape. August 21, 2017.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.